Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
Line 62: Line 62:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 69: Line 69:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 76: Line 77:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
Line 83: Line 85:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 90: Line 93:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
 
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 97: Line 101:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Primary Myelofibrosis (PMF)
 
|Primary Myelofibrosis (PMF)
 
|T. Niroshi Senaratne, UCLA
 
|T. Niroshi Senaratne, UCLA
Line 104: Line 109:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
+
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
 +
| || || || ||FQR|| ||
 
|Juvenile Myelomonocytic Leukemia (JMML)
 
|Juvenile Myelomonocytic Leukemia (JMML)
 
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
 
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 115: Line 121:
 
|FQR has emailed SR several times, last 4/20/22
 
|FQR has emailed SR several times, last 4/20/22
 
|-
 
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 
|Thomas Lee, MD, PhD, University of California, Los Angeles
 
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 122: Line 129:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Cutaneous Mastocytosis
 
|Cutaneous Mastocytosis
 
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
 
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 129: Line 137:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
 
|Systemic Mastocytosis
 
|Systemic Mastocytosis
 
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
 
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
Line 136: Line 144:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Mast Cell Sarcoma
 
|Mast Cell Sarcoma
 
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
 
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 143: Line 152:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
 
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 150: Line 160:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 178: Line 189:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 185: Line 197:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Refractory Cytopenia of Childhood
 
|Refractory Cytopenia of Childhood
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 192: Line 205:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Refractory Cytopenia of Childhood
 
|Refractory Cytopenia of Childhood
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 199: Line 213:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Chronic Myelomonocytic Leukemia (CMML)
 
|Chronic Myelomonocytic Leukemia (CMML)
 
|Linsheng Zhang, MD, PhD
 
|Linsheng Zhang, MD, PhD
Line 206: Line 221:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 
|Linsheng Zhang, MD, PhD
 
|Linsheng Zhang, MD, PhD
Line 213: Line 229:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
 
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 220: Line 237:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
 
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 229: Line 247:
 
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
 
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 245: Line 263:
 
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 261: Line 279:
 
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 277: Line 295:
 
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 293: Line 311:
 
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 309: Line 327:
 
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 325: Line 343:
 
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 341: Line 359:
 
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
 
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 373: Line 391:
 
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
 
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 389: Line 407:
 
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
 
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 405: Line 423:
 
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
 
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 437: Line 455:
 
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
 
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 453: Line 471:
 
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
 
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 469: Line 487:
 
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 485: Line 503:
 
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 501: Line 519:
 
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 517: Line 535:
 
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 533: Line 551:
 
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 549: Line 567:
 
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 565: Line 583:
 
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
 
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 600: Line 618:
 
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
 
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 616: Line 634:
 
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
 
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 632: Line 650:
 
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
 
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 648: Line 666:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 664: Line 682:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 680: Line 698:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 763: Line 781:
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 779: Line 797:
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 811: Line 829:
 
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 827: Line 845:
 
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 843: Line 861:
 
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 875: Line 893:
 
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
 
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 937: Line 955:
 
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
 
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 953: Line 971:
 
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
 
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 969: Line 987:
 
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
 
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,081: Line 1,099:
 
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
 
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,191: Line 1,209:
 
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
 
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,207: Line 1,225:
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,223: Line 1,241:
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,239: Line 1,257:
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,255: Line 1,273:
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
 
|Disease
 
|Disease
|Holli authoring - Complete? Looks like needs more editing of tables
+
|Holli Drendel authoring - Complete? Looks like needs more editing of tables
 
|
 
|
 
|
 
|
Line 1,271: Line 1,289:
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,287: Line 1,305:
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,303: Line 1,321:
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,319: Line 1,337:
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,351: Line 1,369:
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,367: Line 1,385:
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
 
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,448: Line 1,466:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| || || || || ||Shivani Golem (SG)
+
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING
 +
| || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 
|Monoclonal B-cell Lymphocytosis
 
|Monoclonal B-cell Lymphocytosis
Line 1,468: Line 1,487:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||PENDING
 +
| || || || ||SG|| ||
 
|Hairy Cell Leukemia
 
|Hairy Cell Leukemia
 
|Snehal Patel, MD, PhD
 
|Snehal Patel, MD, PhD
Line 1,475: Line 1,495:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||PENDING
 +
| || || || ||SG|| ||
 
|Splenic Marginal Zone Lymphoma
 
|Splenic Marginal Zone Lymphoma
 
|Snehal Patel, MD, PhD
 
|Snehal Patel, MD, PhD
Line 1,482: Line 1,503:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||PENDING
 +
| || || || ||SG|| ||
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
 
|Snehal Patel, MD, PhD
 
|Snehal Patel, MD, PhD
Line 1,491: Line 1,513:
 
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,507: Line 1,529:
 
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
 
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,523: Line 1,545:
 
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
 
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,557: Line 1,579:
 
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
 
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,573: Line 1,595:
 
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
 
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,621: Line 1,643:
 
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
 
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,653: Line 1,675:
 
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
 
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,669: Line 1,691:
 
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
 
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,685: Line 1,707:
 
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
 
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,731: Line 1,753:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
 
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
 
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
 
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
Line 1,745: Line 1,768:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
 
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
Line 1,752: Line 1,776:
 
|
 
|
 
|-
 
|-
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|ALK-Positive Large B-cell Lymphoma
 
|ALK-Positive Large B-cell Lymphoma
 
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
 
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
Line 1,759: Line 1,784:
 
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
 
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
 
|-
 
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|Large B-cell Lymphoma with IRF4 Rearrangement
 
|Large B-cell Lymphoma with IRF4 Rearrangement
 
|Afia Hasnain, MBBS, PhD
 
|Afia Hasnain, MBBS, PhD
Line 1,766: Line 1,792:
 
|
 
|
 
|-
 
|-
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|Burkitt-Like Lymphoma with 11q Aberration
 
|Burkitt-Like Lymphoma with 11q Aberration
 
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
 
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
Line 1,794: Line 1,821:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
+
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING
 +
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
 
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
 
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,808: Line 1,836:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|Plasmablastic Lymphoma
 
|Plasmablastic Lymphoma
 
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 1,815: Line 1,844:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
 
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
 
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
 
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
Line 1,829: Line 1,859:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|Intravascular Large B-cell Lymphoma
 
|Intravascular Large B-cell Lymphoma
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
Line 1,850: Line 1,881:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING
 +
| || || || ||GC|| ||
 
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
 
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
 
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
Line 1,857: Line 1,889:
 
|
 
|
 
|-
 
|-
|Burkitt lymphoma||Disease|| || || || || ||GC|| ||
+
|Burkitt lymphoma||Disease||PENDING
 +
| || || || ||GC|| ||
 
|Burkitt Lymphoma
 
|Burkitt Lymphoma
 
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
 
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
Line 1,922: Line 1,955:
 
|
 
|
 
|-
 
|-
|Classic Hodgkin lymphoma||Disease|| || || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
+
|Classic Hodgkin lymphoma||Disease||PENDING
 +
| || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
 
|GC|| ||
 
|GC|| ||
 
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
 
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
Line 1,975: Line 2,009:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Immunoglobulin-related (AL) amyloidosis||Disease|| || || || || ||SG
+
|Immunoglobulin-related (AL) amyloidosis||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
 
|Primary Amyloidosis
 
|Primary Amyloidosis
Line 1,983: Line 2,018:
 
|
 
|
 
|-
 
|-
|Monoclonal immunoglobulin deposition disease||Disease|| || || || || ||SG
+
|Monoclonal immunoglobulin deposition disease||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
 
|Light Chain and Heavy Chain Deposition Disease
 
|Light Chain and Heavy Chain Deposition Disease
Line 1,999: Line 2,035:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Gamma heavy chain disease||Disease|| || || || || ||SG
+
|Gamma heavy chain disease||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
 
|Gamma Heavy Chain Disease
 
|Gamma Heavy Chain Disease
Line 2,015: Line 2,052:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Plasmacytoma||Disease|| || || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
+
|Plasmacytoma||Disease||PENDING
 +
| || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
 
|SG
 
|SG
 
| ||
 
| ||
Line 2,024: Line 2,062:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Plasma cell myeloma / multiple myeloma||Disease|| || || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG
+
|Plasma cell myeloma / multiple myeloma||Disease||PENDING
 +
| || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG
 
| ||
 
| ||
 
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
 
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
Line 2,032: Line 2,071:
 
|
 
|
 
|-
 
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
+
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||PENDING
 +
| || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
 
|SG
 
|SG
 
| ||
 
| ||
Line 2,102: Line 2,142:
 
|Early T-precursor lymphoblastic leukaemia / lymphoma
 
|Early T-precursor lymphoblastic leukaemia / lymphoma
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 2,132: Line 2,172:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|T-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
+
|T-large granular lymphocytic leukaemia||Disease||PENDING
 +
| || || || ||SK|| ||
 
|T-cell Large Granular Lymphocytic Leukemia
 
|T-cell Large Granular Lymphocytic Leukemia
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,139: Line 2,180:
 
|
 
|
 
|-
 
|-
|NK-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
+
|NK-large granular lymphocytic leukaemia||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Chronic Lymphoproliferative Disorder of NK Cells
 
|Chronic Lymphoproliferative Disorder of NK Cells
 
|Michelle Don, MD
 
|Michelle Don, MD
Line 2,146: Line 2,188:
 
|
 
|
 
|-
 
|-
|Adult T-cell leukaemia/lymphoma||Disease|| || || || || ||SK|| ||
+
|Adult T-cell leukaemia/lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Adult T-cell Leukemia/Lymphoma
 
|Adult T-cell Leukemia/Lymphoma
 
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
 
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
Line 2,153: Line 2,196:
 
|
 
|
 
|-
 
|-
|Sezary syndrome||Disease|| || || || || ||SK|| ||
+
|Sezary syndrome||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Sézary Syndrome
 
|Sézary Syndrome
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,160: Line 2,204:
 
|
 
|
 
|-
 
|-
|Aggressive NK-cell leukaemia||Disease|| || || || || ||SK|| ||
+
|Aggressive NK-cell leukaemia||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Aggressive NK-cell Leukemia
 
|Aggressive NK-cell Leukemia
 
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
 
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
Line 2,181: Line 2,226:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Mycosis fungoides||Disease|| || || || || ||SK|| ||
+
|Mycosis fungoides||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Mycosis Fungoides
 
|Mycosis Fungoides
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,195: Line 2,241:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Primary Cutaneous Anaplastic Large Cell Lymphoma
 
|Primary Cutaneous Anaplastic Large Cell Lymphoma
 
|Theresa Spivey, MD, Shashirekha Shetty, PhD
 
|Theresa Spivey, MD, Shashirekha Shetty, PhD
Line 2,230: Line 2,277:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
+
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
Line 2,244: Line 2,292:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Enteropathy-associated T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|Enteropathy-associated T-cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Enteropathy-Associated T-cell Lymphoma
 
|Enteropathy-Associated T-cell Lymphoma
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
Line 2,251: Line 2,300:
 
|
 
|
 
|-
 
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
Line 2,258: Line 2,308:
 
|
 
|
 
|-
 
|-
|Intestinal T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
+
|Intestinal T-cell lymphoma, NOS||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
 
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
Line 2,265: Line 2,316:
 
|
 
|
 
|-
 
|-
|Hepatosplenic T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|Hepatosplenic T-cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Hepatosplenic T-cell Lymphoma
 
|Hepatosplenic T-cell Lymphoma
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,272: Line 2,324:
 
|
 
|
 
|-
 
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|ALK-positive anaplastic large cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Miguel Gonzalez Mancera, MD
 
|Miguel Gonzalez Mancera, MD
Line 2,283: Line 2,336:
 
|
 
|
 
|-
 
|-
|ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|ALK-negative anaplastic large cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
Line 2,290: Line 2,344:
 
|
 
|
 
|-
 
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|Breast implant-associated anaplastic large cell lymphoma||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
Line 2,313: Line 2,368:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
+
|Nodal TFH cell lymphoma, NOS||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
 
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
Line 2,362: Line 2,418:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| ||
+
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||PENDING
 +
| || || || ||SK|| ||
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Line 2,401: Line 2,458:
 
|Follicular dendritic cell sarcoma
 
|Follicular dendritic cell sarcoma
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|

Revision as of 23:54, 23 December 2023

Welcome!

  • For assignments, please see the "Author" column below (3rd column from left).
    • If empty (no name is present), please volunteer to create content for that disease!
    • If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
  • To volunteer, please [Contact us] with your page of interest.
  • Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added.


WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)



























Clonal haematopoiesis Disease Fabiola Quintero-Rivera (FQR) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Clonal cytopenias of undetermined significance Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Chronic myeloid leukaemia Disease PENDING FQR Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Complete Date page was created
Chronic neutrophilic leukaemia Disease PENDING FQR Chronic Neutrophilic Leukemia (CNL) Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally Complete Date page was created
Chronic eosinophilic leukaemia Disease PENDING FQR Chronic Eosinophilic Leukemia, Not Otherwise Specified Chelsea D. Kramish; Daynna J.Wolff complete/pending faculty review
Polycythaemia vera Disease PENDING FQR Polycythemia Vera (PV) Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center Complete
Essential thrombocythaemia Disease PENDING FQR Essential Thrombocythemia (ET) Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN Complete
Primary myelofibrosis Disease PENDING FQR Primary Myelofibrosis (PMF) T. Niroshi Senaratne, UCLA Complete 8/4/2020 before submission
Juvenile myelomonocytic leukaemia Disease PENDING FQR Juvenile Myelomonocytic Leukemia (JMML) Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology

Associate Director | Division of Molecular Pathology, Genetics and Genomics

Duke University Health System Clinical Laboratories

PENDING importing content and reference formatting FQR has emailed SR several times, last 4/20/22
Myeloproliferative neoplasm, NOS Disease PENDING FQR Myeloproliferative Neoplasm (MPN), Unclassifiable Thomas Lee, MD, PhD, University of California, Los Angeles Complete
Cutaneous mastocytosis Disease PENDING FQR Cutaneous Mastocytosis S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD Complete
Systemic mastocytosis Disease PENDING FQR Systemic Mastocytosis Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University Complete
Mast cell sarcoma Disease PENDING FQR Mast Cell Sarcoma Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL Complete
Myelodysplastic neoplasm with low blasts and 5q deletion Disease PENDING FQR Myelodysplastic Syndrome (MDS) with Isolated del(5q) Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG Complete
Myelodysplastic neoplasm with low blasts and SF3B1 mutation Disease PENDING FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with biallelic TP53 inactivation Disease Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with low blasts Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm, hypoplastic Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with increased blasts Disease PENDING FQR Myelodysplastic Syndrome (MDS) with Excess Blasts Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Childhood myelodysplastic neoplasm with low blasts Disease PENDING FQR Refractory Cytopenia of Childhood Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Childhood myelodysplastic neoplasm with increased blasts Disease PENDING FQR Refractory Cytopenia of Childhood Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Chronic myelomonocytic leukaemia Disease PENDING FQR Chronic Myelomonocytic Leukemia (CMML) Linsheng Zhang, MD, PhD Complete
Myelodysplastic/myeloproliferative neoplasm with neutrophilia Disease PENDING FQR Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Linsheng Zhang, MD, PhD Complete
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis Disease PENDING FQR Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine Complete Date page was created
Myelodysplastic/myeloproliferative neoplasm, NOS Disease PENDING FQR Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia Complete
Acute promyelocytic leukaemia with PML::RARA fusion Disease PENDING Jennelle Hodge (JH)/ Malini Sathanoori (MS) Acute Promyelocytic Leukemia (APL) with PML-RARA Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA
Complete 04/26/2021-MS (re-review)
Acute myeloid leukaemia with CBFB::MYH11 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA
Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with DEK::NUP214 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Jennelle C. Hodge, PhD, FACMG Complete 02/24/2021-MS (re-review)
Acute myeloid leukaemia with RBM15::MRTFA fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Jennelle C. Hodge, PhD, FACMG Complete
Acute myeloid leukaemia with BCR::ABL1 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with BCR-ABL1 Kay Weng Choy MBBS, Monash Medical Centre Complete
Acute myeloid leukaemia with KMT2A rearrangement Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with MECOM rearrangement Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Gordana Raca MD PhD, University of Southern California, Los Angeles Complete Need permission for figure? Update WHO?
Acute myeloid leukaemia with NUP98 rearrangement Disease Eric McGinnis, MD 12/20/23 JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute myeloid leukaemia with NPM1 mutation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Mutated NPM1 Xinjie Xu, PhD, FACMG Complete Add WHO reference
Acute myeloid leukaemia with CEBPA mutation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Paul Defazio, MSc, Monash Health Complete
Acute myeloid leukaemia, myelodysplasia-related Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Acute myeloid leukaemia with other defined genetic alterations Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute myeloid leukaemia with minimal differentiation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Minimal Differentiation Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine Complete
Acute myeloid leukaemia without maturation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) without Maturation Jennelle C. Hodge, PhD, FACMG Complete
Acute myeloid leukaemia with maturation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Maturation Jennelle C. Hodge, PhD, FACMG Complete
Acute basophilic leukaemia Disease PENDING JH_MS Acute Basophilic Leukemia Ashwini Yenamandra PhD FACMG Complete
Acute myelomonocytic leukaemia Disease PENDING JH_MS Acute Myelomonocytic Leukemia Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Acute monocytic leukaemia Disease PENDING JH_MS Acute Monoblastic and Monocytic Leukemia Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Acute erythroid leukaemia Disease PENDING JH_MS Pure Erythroid Leukemia Ashwini Yenamandra PhD FACMG Complete
Acute megakaryoblastic leukaemia Disease PENDING JH_MS Acute Megakaryoblastic Leukemia (AMKL) Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Myeloid sarcoma Disease PENDING JH_MS Myeloid Sarcoma Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine Complete
RESOLVE 4th edition AML-Related NON-WHO entities content Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 ISSUE- FIX


Resolve Non-WHO entities

Myeloid neoplasm post cytotoxic therapy Disease PENDING JH_MS Therapy-Related Myeloid Neoplasms Shawn A. Silver, DO, Shashi Shetty, Ph.D. Complete Check reference format
Myeloid neoplasms associated with germline predisposition Disease PENDING JH_MS Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation) See links from instructions on the 5th edition page Complete Most were re-reviewed by MS on 03/02/2021 For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
Myeloid proliferations associated with Down syndrome Disease PENDING JH_MS MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO Complete (all three pages)
Myeloid/lymphoid neoplasm with PDGFRA rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Jay Alden, DO Complete
Myeloid/lymphoid neoplasm with PDGFRB rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD Complete
Myeloid/lymphoid neoplasm with FGFR1 rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Yanna Ding, MD PhD Complete
Myeloid/lymphoid neoplasm with JAK2 rearrangement Disease ISSUE- FIX


Resolve Non-WHO entities

FQR Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff Complete
Myeloid/lymphoid neoplasm with FLT3 rearrangement Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Tracy Tucker, PhD, FCCMG Complete
Mixed-phenotype acute leukaemia with KMT2A rearrangement Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Tracy Tucker, PhD, FCCMG Complete
Acute leukaemia of ambiguous lineage with other defined genetic alterations Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mixed-phenotype acute leukaemia, B/myeloid Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD Complete
Mixed-phenotype acute leukaemia, T/myeloid Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine Complete
Mixed-phenotype acute leukaemia, rare types Disease PENDING JH_MS Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina PENDING
Acute leukaemia of ambiguous lineage, NOS Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute undifferentiated leukaemia Disease PENDING JH_MS Acute Undifferentiated Leukemia Amelia Nakanishi, MD and Shashi Shetty, PhD Complete Check reference format
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)



























Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm Disease Greg Corboy (GC) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Blastic plasmacytoid dendritic cell neoplasm Disease PENDING GC Blastic Plasmacytoid Dendritic Cell Neoplasm Hao Liu, MD and Daynna J. Wolff, PhD Complete Previously within myeloid section under JH/MS editors
Langerhans cell histiocytosis Disease PENDING GC Langerhans Cell Histiocytosis Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland Complete 5/19/2022
Date completed by author: 04/28/2022
Langerhans cell sarcoma Disease PENDING GC Langerhans Cell Sarcoma Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland Complete 5/19/2022
Date completed by author: 04/28/2022
Indeterminate dendritic cell tumour Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Interdigitating dendritic cell sarcoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Juvenile xanthogranuloma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Erdheim-Chester disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Rosai-Dorfman Disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
ALK-positive histiocytosis Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Histiocytic sarcoma Disease PENDING GC Histiocytic Sarcoma Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic Complete 10/01/2021 Date completed by author: 10/01/2021
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)



























Reactive B-cell rich lymphoid proliferations that can mimic lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
IgG4-related disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Unicentric Castleman disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Idiopathic multicentric Castleman disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-associated multicentric Castleman disease Disease PENDING GC Multicentric Castleman Disease Sudha Arumugam, MD Complete 01/24/2022 Date completed by author: 01/24/2022
B-lymphoblastic leukaemia/lymphoma Disease PENDING Holli Drendel (HD) B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Holli Drendel PENDING
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG PENDING
B-lymphoblastic leukaemia/lymphoma with hypodiploidy Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG Complete
B-lymphoblastic leukaemia/lymphoma with iAMP21 Disease Holli Drendel authoring - Complete? Looks like needs more editing of tables HD B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte ?Complete
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG PENDING
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine Complete
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Yassmine Akkari Nicolas Millan PENDING
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Disease PENDING HD B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma PENDING
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO PENDING
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO PENDING
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma, NOS Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
RESOLVE 4th edition ALL-Related NON-WHO entities content B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) ISSUE- FIX


Resolve Non-WHO entities

ISSUE - FIX
Monoclonal B-cell lymphocytosis Disease PENDING Shivani Golem (SG) Monoclonal B-cell Lymphocytosis Tsigab Bahta Hagos (trainee) / Shashirekha Shetty PENDING Assigned 12/19/2022 with completion date of 1/19/2023
Chronic lymphocytic leukaemia/small lymphocytic lymphoma Disease Jaime Nagy, PhD, University of Iowa

Renee Eigsti, MD, Pathology Services of Kalamazoo

Honey Reddi, PhD, Belay Diagnostics

Complete (Shivani, please confirm) SG Already converted to 5th edition Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD
Hairy cell leukaemia Disease PENDING SG Hairy Cell Leukemia Snehal Patel, MD, PhD Complete
Splenic marginal zone lymphoma Disease PENDING SG Splenic Marginal Zone Lymphoma Snehal Patel, MD, PhD Complete
Splenic diffuse red pulp small B-cell lymphoma Disease PENDING SG Splenic Diffuse Red Pulp Small B-cell Lymphoma Snehal Patel, MD, PhD Complete
Splenic B-cell lymphoma/leukaemia with prominent nucleoli Disease PENDING SG Hairy Cell Leukemia Variant Snehal Patel, MD, PhD Complete
Lymphoplasmacytic lymphoma Disease PENDING SG (1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia (1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) Complete 4/12/2023 by FQR
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue Disease PENDING SG Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*

Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)

Complete 4/12/23 by FQR
Primary cutaneous marginal zone lymphoma Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Nodal marginal zone lymphoma Disease PENDING SG Nodal Marginal Zone Lymphoma Andrew Ly, DO and Shivani Golem, PhD, FACMG Complete 5/28/2021
Paediatric nodal marginal zone lymphoma Disease PENDING SG Paediatric Nodal Marginal Zone Lymphoma * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD Complete 11/11/2020
In situ follicular B-cell neoplasm Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG In Situ Follicular Neoplasia Rachel D. Burnside, PhD, MBA, FACMGG Pending
Follicular lymphoma Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity (1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma (1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida Pending
Paediatric-type follicular lymphoma Disease PENDING SG Paediatric-Type Follicular Lymphoma *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG Complete 8/16/2020
Duodenal-type follicular lymphoma Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG Duodenal-Type Follicular Lymphoma No prior content
Primary cutaneous follicle centre lymphoma Disease PENDING SG Primary Cutaneous Follicle Centre Lymphoma Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG Complete 09/10/2022
In situ mantle cell neoplasm Disease PENDING SG In Situ Mantle Cell Neoplasia Rina Kansal, MD; Versiti Blood Center of Wisconsin Complete 7/26/2022
Mantle cell lymphoma Disease PENDING SG Mantle Cell Lymphoma * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas Pending Target completion date 8/15/20
Leukaemic non-nodal mantle cell lymphoma Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Transformations of indolent B-cell lymphomas Disease SG Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma, NOS Disease PENDING GC Diffuse Large B-cell Lymphoma, Not Otherwise Specified Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center Pending Requested to update 14022022
T-cell/histiocyte-rich large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements Disease PENDING GC High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Kate Berry, MBBS, BBus (Hons), Pathology Queensland Complete 24/02/2022
ALK-positive large B-cell lymphoma Disease PENDING GC ALK-Positive Large B-cell Lymphoma Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) Pending Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
Large B-cell lymphoma with IRF4 rearrangement Disease PENDING GC Large B-cell Lymphoma with IRF4 Rearrangement Afia Hasnain, MBBS, PhD Complete 5/26/2021
High grade B-cell lymphoma with 11q aberrations Disease PENDING GC Burkitt-Like Lymphoma with 11q Aberration Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina Comlete 27/01/2022
Lymphomatoid granulomatosis Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
EBV-positive diffuse large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma associated with chronic inflammation Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fibrin-associated large B-cell lymphoma Disease PENDING GC Note: previously a subset DLBCL assoc with chronic inflam Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fluid overload-associated large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasmablastic lymphoma Disease PENDING GC Plasmablastic Lymphoma Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Complete 28/03/2022
Primary large B-cell lymphoma of immune-privileged sites Disease PENDING GC (1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS (1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital (1) Pending + (2) Complete (1) Not ready + (2) 03/28/22 For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
Primary cutaneous diffuse large B-cell lymphoma, leg type Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Intravascular large B-cell lymphoma Disease PENDING GC Intravascular Large B-cell Lymphoma Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy Complete 9/1/22 Emailed 28/3/2022 for progress update
Primary mediastinal large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mediastinal grey zone lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
High-grade B-cell lymphoma, NOS Disease PENDING GC High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) Aiko Otsubo, PhD, Indiana University, Holli Drendel Complete 16/11/2021
Burkitt lymphoma Disease PENDING GC Burkitt Lymphoma Becky Leung, MBBS (Hons), BSc, Pathology Queensland Complete 28/06/2021
Primary effusion lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-positive diffuse large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-positive germinotropic lymphoproliferative disorder Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Hyperplasias arising in immune deficiency/dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others") GC
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders.

Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"

GC Polymorphic Post-Transplant Lymphoproliferative Disorders Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) Completed 26/4/2022
EBV-positive mucocutaneous ulcer Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Lymphomas arising in immune deficiency / dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others" GC
Inborn error of immunity-associated lymphoid proliferations and lymphomas Disease FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") GC
Classic Hodgkin lymphoma Disease PENDING Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma GC (1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma (1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez Pending + Completed (03/21/22) Not completed for checking (1, 3 and 4) + 03/21/22 (2)
Nodular lymphocyte predominant Hodgkin lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Cold agglutinin disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
IgM monoclonal gammopathy of undetermined significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Non-IgM monoclonal gammopathy of undetermined significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Monoclonal gammopathy of renal significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Immunoglobulin-related (AL) amyloidosis Disease PENDING SG Primary Amyloidosis Heather E. Williams, PhD, MS, PgD, ErCLG ?PENDING
Monoclonal immunoglobulin deposition disease Disease PENDING SG Light Chain and Heavy Chain Deposition Disease Chen Yang, MD, PhD, University of Michigan Complete 10/15/2022
Mu heavy chain disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Gamma heavy chain disease Disease PENDING SG Gamma Heavy Chain Disease Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA Complete 5/26/2021
Alpha heavy chain disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasmacytoma Disease PENDING author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) SG NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasma cell myeloma / multiple myeloma Disease PENDING Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page SG (1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants (1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG Pending
Plasma cell neoplasms with associated paraneoplastic syndrome Disease PENDING Note: author needs to include POEMS, TEMPI, and look for AESOP content SG (1) POEMS Syndrome + (2) TEMPI Syndrome (1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD ?PENDING
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)



























Kikuchi-Fujimoto disease Disease Sumi Kitahara (SK) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Autoimmune lymphoproliferative syndrome Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Indolent T-lymphoblastic proliferation Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
T-lymphoblastic leukaemia / lymphoma, NOS Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Early T-precursor lymphoblastic leukaemia / lymphoma Disease PENDING HD Early T-Cell Precursor Lymphoblastic Leukemia Fei Yang, MD, FACMG, Kaiser Permanente Northwest Pending
T-prolymphocytic leukaemia Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
T-large granular lymphocytic leukaemia Disease PENDING SK T-cell Large Granular Lymphocytic Leukemia Michelle Don, MD, MS Pending
NK-large granular lymphocytic leukaemia Disease PENDING SK Chronic Lymphoproliferative Disorder of NK Cells Michelle Don, MD Pending
Adult T-cell leukaemia/lymphoma Disease PENDING SK Adult T-cell Leukemia/Lymphoma Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center ?Pending
Sezary syndrome Disease PENDING SK Sézary Syndrome Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina Pending
Aggressive NK-cell leukaemia Disease PENDING SK Aggressive NK-cell Leukemia Shanelle De Lancy, MD, Shashirekha Shetty, PhD ?Pending
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mycosis fungoides Disease PENDING SK Mycosis Fungoides Jane Scribner, MD and Daynna J. Wolff, PhD Pending
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma Disease PENDING SK Primary Cutaneous Anaplastic Large Cell Lymphoma Theresa Spivey, MD, Shashirekha Shetty, PhD Pending
Subcutaneous panniculitis-like T-cell lymphoma Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous gamma/delta T-cell lymphoma Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous peripheral T-cell lymphoma, NOS Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Indolent T-cell lymphoma of the gastrointestinal tract Disease PENDING SK Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD Pending
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Enteropathy-associated T-cell lymphoma Disease PENDING SK Enteropathy-Associated T-cell Lymphoma *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD Complete 1/21/2021
Monomorphic epitheliotropic intestinal T-cell lymphoma Disease PENDING SK Monomorphic Epitheliotropic Intestinal T-cell Lymphoma Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD Pending
Intestinal T-cell lymphoma, NOS Disease PENDING SK Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) Complete 9/26/2022
Hepatosplenic T-cell lymphoma Disease PENDING SK Hepatosplenic T-cell Lymphoma Michelle Don, MD, MS Complete 1/21/2021
ALK-positive anaplastic large cell lymphoma Disease PENDING SK Anaplastic Large Cell Lymphoma, ALK-Positive Miguel Gonzalez Mancera, MD

Sumire Kitahara, MD

Cedars-Sinai, Los Angeles, CA

Complete 09/23/2022
ALK-negative anaplastic large cell lymphoma Disease PENDING SK Anaplastic Large Cell Lymphoma, ALK-Negative Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA Complete 09/23/2022
Breast implant-associated anaplastic large cell lymphoma Disease PENDING SK Breast Implant-Associated Anaplastic Large Cell Lymphoma Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center Pending
Nodal TFH cell lymphoma, angioimmunoblastic-type Disease Issue - Rachel Burnside was working on this. Note says: "has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)". Where is her content as previous author names on 5th edition page 7/28/2023 Pending SK Angioimmunoblastic T-cell Lymphoma Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG Pending
Nodal TFH cell lymphoma, follicular-type Disease Rachel Burnside 7/28/2023 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Nodal TFH cell lymphoma, NOS Disease PENDING SK Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD Pending
Peripheral T-cell lymphoma, NOS Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
EBV-positive nodal T- and NK-cell lymphoma Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Extranodal NK/T-cell lymphoma Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Severe mosquito bite allergy Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Hydroa vacciniforme lymphoproliferative disorder Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Systemic chronic active EBV disease Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Systemic EBV-positive T-cell lymphoma of childhood Disease PENDING SK Systemic EBV-Positive T-cell Lymphoma of Childhood Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA Complete 11/21/2021
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)



























Follicular dendritic cell sarcoma Disease PENDING GC Follicular Dendritic Cell Sarcoma Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG ?Pending
EBV-positive inflammatory follicular dendritic cell sarcoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fibroblastic reticular cell tumour Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Intranodal palisaded myofibroblastoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Littoral cell angioma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Splenic hamartoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Sclerosing angiomatoid nodular transformation (SANT) of spleen Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
CHAPTER 7 (GENETIC TUMOUR SYNDROMES)



























Fanconi anaemia Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Bloom syndrome Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Ataxia-telangiectasia syndrome Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
RASopathies Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)